Markets
United States Antimony Stock Soars 17%, Adding $73 Million After A Monthlong Slide
Shares remain 74% below their 52-week high, with third-quarter results scheduled for Thursday.
Product + growth @TheBullished. I build the software that writes the stories you read, and get them in front of as many people as possible.
Markets
Shares remain 74% below their 52-week high, with third-quarter results scheduled for Thursday.
Markets
Revenue rose 6.3% from the second quarter, while management expects to end the year debt-free with about $70 million in cash.
Markets
Expected net proceeds of about $80.5 million would fund operations into late fourth quarter 2027, versus an earlier first-quarter horizon.
Earnings
Analysts questioned how Jacobs would balance another company with QXO's acquisition integration and 2030 earnings targets.
Markets
Acquired businesses enter the sales comparison as QXO prepares to publish full third-quarter results Thursday.
Earnings
Management plans to add services before aligning acquired businesses’ fees, while keeping pricing suited to different asset markets.
Markets
The lower dose failed to outperform placebo, while management plans FDA talks later this year on a path toward approval.
Markets
Adjusted earnings rose about 8%, but prior-year tax benefits left reported earnings about 5% lower.
Earnings
A delayed connectivity deal is signed, but higher memory prices are squeezing smartphones, PCs and televisions.
Markets
The gain added $259 million in market value, extending a run that had already put shares up 103% this year through Friday.
Markets
The operating loss widened despite revenue growth, while management expected the company's highest quarterly revenue.
Earnings
Management plans an auto-injector launch in 2028, while raising its U.S. product-sales forecast to $915–920 million.